EP2 antagonists(Prostanoid EP2 receptor antagonists), EP4 antagonists(Prostanoid EP4 receptor antagonists), sGC modulators(Soluble guanylate cyclase modulators)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication

AsthmaPulmonary Disease, Chronic Obstructive

Inactive Indication-

Originator Organization

Gurus Biopharm, Inc.

Active Organization

Gurus Biopharm, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

100 Clinical Results associated with GUR-501

100 Translational Medicine associated with GUR-501

100 Patents (Medical) associated with GUR-501

Literatures (Medical) associated with GUR-501

01 Nov 2024·American Journal of Obstetrics & Gynecology MFM

Results of the RE-DINO multicenter randomized trial on the repeated use of vaginal dinoprostone (Propess®) for labor induction in patients at term

Article

Author: GALLOT, Pr. Denis ; Crépin, Sabrina ; Magne, Julien ; Gallot, Denis ; Siegerth, François ; Cantaloube, Muriel ; BIGOT, Dr. Angeline GARUCHET ; Labrunie, Anais ; MAGNE, Pr. Julien ; SIEGERTH, Dr. François ; Martin, Renaud ; CRÉPIN, Dr. Sabrina ; Blanc, Julie ; CANTALOUBE, Dr. Muriel ; Decroisette, Emmanuel ; HESSAS, Dr. Miassa ; COSTE-MAZEAU, MD-PhD. Perrine ; LABRUNIE, Ms. Anais ; Garuchet-Bigot, Angeline ; MARTIN, Dr. Renaud ; DECROISETTE, Dr. Emmanuel ; Coste-Mazeau, Perrine ; Hessas, Miassa ; BLANC, Pr. Julie

BACKGROUNDLabor is induced in over 25% of women in France. Prostaglandins, especially intravaginal dinoprostone (Propess®), are widely used to initiate cervical ripening. If labor does not start within 24 hours, there is uncertainty about whether to administer a second dinoprostone pessary or to use oxytocin to induce labor in order to achieve a vaginal delivery.OBJECTIVESOur principal objective was to determine whether placement of a second Propess®, followed by oxytocin (Syntocinon®) if necessary, in pregnant women for whom the first Propess® failed to induce cervical ripening increases the vaginal delivery rate compared to direct oxytocin injection. The vaginal delivery rate was therefore the primary outcome. The secondary outcomes were the cervical ripening failure rate and maternal and fetal morbidity and mortality.STUDY DESIGNRE-DINO is a prospective, open-label, multicenter, randomized superiority trial with 2 parallel arms running in 7 French hospitals. Patients at > 37 weeks of gestation who had unfavorable cervical conditions (Bishop score < 6) 24 hours after placement of the first Propess® (vaginal patch featuring progressive continuous diffusion of 10 mg dinoprostone), with fetuses in cephalic presentation, were included.RESULTS160 pregnant women were randomized, 80 patients in each group, from December 2016 through April 2022. Baseline characteristics such as age, BMI, maternal age at induction and Bishop score at induction were similar between both groups. Vaginal delivery occurred in 76.3% of cases in the 2nd Propess® group and 73.8% of cases in the Syntocinon® group (RR=1.03 [0.86; 1.24], p=.715). Although the cesarean section rate was similar in each group, there were significantly more cesarean sections for arrest of dilatation (52.6% vs 19%; p=.0262) in the Propess® group and a larger, borderline-significant difference in patients having operative vaginal delivery (24.6% vs 11.9%; p=.07) for abnormal fetal heart rate (80% vs 29%; p=.05). There was significantly more failure of cervical ripening in the Propess® group (57.1% vs 19%; RR=2.59 ; 95% CI [1.64; 4.11]; p<.0001) and the interval between study treatment and delivery was also significantly longer (28.1h vs 9,7h; p<.0001). There was a higher incidence of postpartum hemorrhage in the Propess® group, although this was not significant (11.3% vs 5% ; p=,15), but also more newborns with acidosis (39.3% vs 27.9% ; p=.18) or severe acidosis (8,6% vs 3.4% ; p=.27), more meconium fluid (11.3% vs 6.3% ; p=.26) and transferred to intensive care (5% vs 2.5% ; p=.68).CONCLUSIONOur data showed no superiority of a second dinoprostone pessary over oxytocin in patients not responding to initial prostaglandins E2 maturation for labor induction. Repeated use of Propess® is not useful for induction of labor.

100 Deals associated with GUR-501

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 1	-	Gurus Biopharm, Inc.	-
Pulmonary Disease, Chronic Obstructive	Phase 1	-	Gurus Biopharm, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

GUR-501

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation